Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)

CompletedOBSERVATIONAL
Enrollment

153

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
Infectious DiseaseCancerCoronavirus Infection
Interventions
DIAGNOSTIC_TEST

Throat/nose swabs

Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.

DIAGNOSTIC_TEST

Saliva collection

Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5 millilitres (mL)) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.

DIAGNOSTIC_TEST

Blood collection

Approximately 30mL of blood will be taken at each study visit.

Trial Locations (1)

SM2 5PT

The Royal Marden NHS Foundation Trust, Sutton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

St George's, University of London

OTHER

collaborator

Mologic Ltd

INDUSTRY

collaborator

The Royal Marsden Cancer Charity

UNKNOWN

collaborator

National Institute for Health Research Biomedical Research Centre

UNKNOWN

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT04427280 - Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19) | Biotech Hunter | Biotech Hunter